Table 6 Cumulative percent of patients with AEs (302/304 pooled population)
From: Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease
| Â | Placebo | Donepezil 5 mg | Donepezil 10 mg | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | 1 week | 2 weeks | 4 weeks | Total duration | 1 week | 2 weeks | 4 weeks | Total duration | 1 week* | 2 weeks | 4 weeks | Total duration |
Number (%) of subjects with at least 1 such AE | 92 (21.1) | 122 (28.0) | 171 (39.2) | 329 (75.5) | 98 (23.1) | 126 (29.6) | 176 (41.4) | 331 (77.9) | 118 (27.4) | 201 (48.1) | 252 (58.6) | 361 (84.0) |
Number (%) of subjects who discontinued due to AE | 8 (1.8) | 11 (2.5) | 14 (3.2) | 27 (6.2) | 5 (1.2) | 8 (1.9) | 10 (2.4) | 20 (4.7) | 9 (2.1) | 24 (5.6) | 38 (8.8) | 65 (15.1) |
   Vomiting | 2 (0.5) | 2 (0.5) | 3 (0.7) | 13 (3.0) | 7 (1.6) | 9 (2.1) | 10 (2.4) | 17 (4.0) | 13 (3.0) | 38 (8.8) | 47 (10.9) | 59 (13.7) |
   Nausea | 6 (1.4) | 11 (2.5) | 14 (3.2) | 25 (5.7) | 15 (3.5) | 16 (3.8) | 19 (4.5) | 26 (6.1) | 22 (5.1) | 62 (14.4) | 78 (18.1) | 92 (21.4) |
   Diarrhea | 4 (0.9) | 6 (1.4) | 9 (2.1) | 22 (5.0) | 9 (2.1) | 15 (3.5) | 18 (4.2) | 42 (9.9) | 14 (3.3) | 31 (7.2) | 45 (10.5) | 73 (17.0) |
   Dizziness | 4 (0.9) | 8 (1.8) | 10 (2.3) | 21 (4.8) | 8 (1.9) | 14 (3.3) | 15 (3.5) | 28 (6.6) | 9 (2.1) | 20 (4.7) | 26 (6.0) | 38 (8.8) |
   Headache | 9 (2.1) | 10 (2.3) | 19 (4.4) | 50 (11.5) | 7 (1.6) | 11 (2.6) | 20 (4.7) | 41 (9.6) | 17 (4.0) | 31 (7.2) | 36 (8.4) | 57 (13.3) |